The US Food and Drug Administration (FDA) on Tuesday released a warning letter sent to Orange, CA-based distributor NuCare Pharmaceuticals after the company failed to correct certain drug listings.

The FDA has moved to exclude semaglutide, tirzepatide and liraglutide -- which are in several popular weight loss drugs -- from its 503B bulks list.

The FDA said Walgreens has addressed violations related to drug listing deficiencies for one of its products, according to a Dec. 19 close-out letter. The agency previously cited Walgreens in ...

The FDA has proposed excluding weight-loss drugs, such as Ozempic/Wegovy and Zepbound from a key compounding list, ...

On April 16, 2026, the U.S. Food & Drug Administration (FDA) announced it will convene the Pharmacy Compounding Advisory Committee (PCAC) on July ...

If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines ​unless they appear on the FDA's ⁠drug shortage ⁠list.

By Mariam Sunny April 30 (Reuters) - The U.S. Food and Drug Administration on Thursday proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding list, potentially ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for removing semaglutide, the active ingredient in Ozempic, from its drug shortage ...

Editor's note: this article was updated with comments from Prestige Brands Holdings. The US Food and Drug Administration (FDA) on Thursday warned over-the-counter drugmaker Prestige Brands Holdings ...

Patients are advised to get a prescription from their doctor and to fill the prescription at a licensed pharmacy or use the FDA's BeSafeRx campaign to determine where to safely buy medications online.